Search

Vertex Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

477.26 0.78

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

470.19

Макс.

483.59

Ключевые показатели

By Trading Economics

Доход

-160M

1B

Продажи

-240M

3B

P/E

Средняя по отрасли

28.824

62.58

Прибыль на акцию

4.47

Рентабельность продаж

34.531

Сотрудники

6,400

EBITDA

-45M

1.3B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+18.11% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

14B

122B

Предыдущая цена открытия

476.48

Предыдущая цена закрытия

477.26

Новостные настроения

By Acuity

12%

88%

15 / 340 Рейтинг в Healthcare

Vertex Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

22 июл. 2026 г., 20:06 UTC

Social Media

Vertex Pharmaceuticals is lower amid market volatility and uncertainty ahead of the Federal Reserve meeting, reflecting a cumulative decline since Tuesday's close.

20 июл. 2026 г., 18:41 UTC

News

Vertex Pharmaceuticals shares are lower amid a broader decline in the Biotechnology sector. The company recently completed a $10 billion acquisition to enhance its portfolio.

17 июл. 2026 г., 18:56 UTC

Vertex Pharmaceuticals shares are declining amid broader market pressures from rising oil prices and inflation concerns linked to military actions in the Gulf region.

16 июл. 2026 г., 19:51 UTC

Biotechnology stocks are advancing, supporting Vertex Pharmaceuticals' upward movement. This marks a shift from the recent trend of higher daily closes.

15 июл. 2026 г., 18:36 UTC

News

Vertex Pharmaceuticals agrees to acquire Crinetics Pharmaceuticals for $85 per share. Shares are higher as analysts view the deal positively amid easing inflation pressures.

14 июл. 2026 г., 23:16 UTC

Vertex Pharmaceuticals Inc shares are trading lower in after-market hours, continuing a trend of six consecutive daily declines without any specific news to explain the movement.

13 июл. 2026 г., 19:06 UTC

News
Social Media

Vertex Pharmaceuticals announced an agreement to acquire Crinetics for $85 per share, valued at $10 billion, while shares are lower during Monday's session.

10 июл. 2026 г., 20:02 UTC

News

Vertex Pharmaceuticals is lower today amid significant declines in the Biotechnology sub-sector, marking a shift from recent higher daily closes.

9 июл. 2026 г., 23:16 UTC

Vertex Pharmaceuticals shares are lower in after-market trading, with no specific news identified to explain the movement amid broader market sentiment influenced by U.S.-Iran tensions.

8 июл. 2026 г., 23:46 UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite significant declines in European markets amid geopolitical tensions involving the U.S. and Iran.

7 июл. 2026 г., 19:36 UTC

News
Social Media

Vertex Pharmaceuticals shares are lower today following its $10 billion acquisition of Crinetics Pharmaceuticals, despite analyst support and price target increases.

6 июл. 2026 г., 23:02 UTC

Social Media
News

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

2 июл. 2026 г., 20:03 UTC

News
Social Media
Event

Vertex Pharmaceuticals shares are higher following FDA approval for expanded use of CASGEVY, now available for children as young as 2 years old.

1 июл. 2026 г., 20:06 UTC

Vertex Pharmaceuticals shares are advancing, reflecting broader market trends. The stock remains above its 20-day moving average despite an earlier session pullback.

30 июн. 2026 г., 20:07 UTC

News

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

29 июн. 2026 г., 19:31 UTC

News

Vertex Pharmaceuticals is trading higher, driven by positive analyst sentiment and revised earnings estimates ahead of its upcoming earnings report.

26 июн. 2026 г., 20:04 UTC

Vertex Pharmaceuticals is rising as biotechnology stocks advance during Friday's session. The stock remains above its 20-day moving average after five consecutive higher closes.

25 июн. 2026 г., 20:02 UTC

Vertex Pharmaceuticals is trading higher today amid notable volatility, reflecting a broader trend since Wednesday's close, despite no specific company news.

24 июн. 2026 г., 23:26 UTC

Vertex Pharmaceuticals is lower in after-market hours, driven by declines in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

23 июн. 2026 г., 19:36 UTC

Vertex Pharmaceuticals shares are higher today, recovering from an earlier pullback. The stock remains near the upper end of its one-month trading range.

22 июн. 2026 г., 20:02 UTC

News

Vertex Pharmaceuticals is higher today, supported by a diverse pipeline in kidney disease and favorable market conditions following easing U.S.-Iran tensions.

18 июн. 2026 г., 19:52 UTC

Vertex Pharmaceuticals shares are lower today as biotechnology stocks face pressure. Earlier in the session, shares peaked before reversing direction.

17 июн. 2026 г., 19:54 UTC

Macro Event

Vertex Pharmaceuticals is rising amid a positive Biotechnology sector trend and favorable Federal Reserve interest rate decisions, boosting investor confidence in healthcare.

16 июн. 2026 г., 23:16 UTC

Vertex Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment is influenced by optimism over a potential U.S.-Iran peace deal.

15 июн. 2026 г., 12:46 UTC

Vertex Pharmaceuticals is roughly flat in pre-market hours, maintaining a routine performance and remaining above its 20-day moving average.

12 июн. 2026 г., 19:36 UTC

Vertex Pharmaceuticals shares are higher today, reflecting stable trading conditions. The stock is positioned above its 20-day moving average, indicating positive market sentiment.

11 июн. 2026 г., 23:56 UTC

Event

Vertex Pharmaceuticals announced clinical benefits of CASGEVY® for severe sickle cell disease. Shares are trading lower in after-market hours, within a typical trading range.

10 июн. 2026 г., 20:03 UTC

Macro Event

Vertex Pharmaceuticals shares are lower as inflation data aligns with forecasts. The stock continues to trade below its 20-day moving average.

9 июн. 2026 г., 19:56 UTC

Vertex Pharmaceuticals shares are higher during Tuesday's session, having peaked earlier, though they have pulled back slightly. No specific news was identified for this movement.

8 июн. 2026 г., 19:36 UTC

Event

Vertex Pharmaceuticals shares are lower despite positive data on ALYFTREK for cystic fibrosis. The decline follows broader market dynamics after a strong U.S. jobs report.

Сравнение c конкурентами

Изменение цены

Vertex Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

18.11% рост

Прогноз на 12 месяцев

Средняя 558.78 USD  18.11%

Максимум 652 USD

Минимум 350 USD

Основано на мнении 27 аналитиков Wall Street, спрогнозировавших целевые цены для Vertex Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

27 ratings

21

Покупка

5

Удержание

1

Продажа

Настроения

By Acuity

15 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
help-icon Live chat